LeMaitre Vascular beat Q4 sales expectations, raises dividend

Lemaitre Vascular

25/02/2026 21:46

Overview

Vascular device provider's Q4 sales rose 16%, beating analyst expectations

Diluted EPS for Q4 increased 39%, driven by higher ASPs and manufacturing efficiencies

Company announced $100 mln share repurchase program and 25% dividend increase

Outlook

LeMaitre Vascular expects Q1 2026 sales between $65.6 mln and $67.6 mln

Company forecasts full-year 2026 sales at $276 mln to $284 mln

LeMaitre Vascular projects Q1 2026 EPS between $0.64 and $0.69

Result Drivers

PRODUCT LINE GROWTH - Grafts, valvulotomes, and carotid shunts drove Q4 sales growth, with increases of 27%, 20%, and 18% respectively

REGIONAL SALES INCREASE - EMEA sales rose 29%, APAC 20%, and the Americas 10%, contributing to overall sales growth

MARGIN IMPROVEMENT - Gross margin increased to 71.7% due to higher average selling prices and manufacturing efficiencies

Company press release: ID:nGNX8vyq8v

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$64.45 mln
$62.82 mln (11 Analysts)
Q4 Net Income
$15.58 mln
Q4 Gross Profit
$46.19 mln
Q4 Income From Operations
$18.83 mln
Q4 Pretax Profit
$20.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LeMaitre Vascular Inc is $108.00, about 19% above its February 24 closing price of $90.75

The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 35 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)